Long COVIDNCT06974058
Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms
A study testing Nasafytol® (Quercetin/Curcumin Supplement) in people with Long COVID, run by Liaquat University of Medical & Health Sciences at 1 site in Pakistan.
Trial summary
This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Long COVID
- What is being tested?
- Nasafytol® (Quercetin/Curcumin Supplement)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 sitePakistan
- Study dates
- 22 Jul 2025to 14 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age: 18 to 75 years.
- History of confirmed COVID-19 infection at least 6 months prior to the enrollment.
- Persistent mild to moderate COVID-19 symptoms for at least 3 months post-acute infection.
- Diagnosis of Long COVID-19 based on WHO criteria.
- Symptom burden score of ≥25 at baseline (V0) on the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS).
- At least one symptom scoring between 1-7 on the C19-YRS.
- Stable medical condition: No recent hospitalization (past 3 months) due to acute illness.
- Willing and able to adhere to the study protocol, including follow-up visits, symptom reporting, and compliance with supplementation
Who cannot join
- Hypersensitivity or allergy to quercetin, curcumin, or any component of the supplement (Nasafytol®).
- Severe, uncontrolled chronic illness (e.g., severe heart failure, chronic kidney disease requiring dialysis, severe liver disease).
- Regular use of quercetin or curcumin supplements within the last 3 months.
- Use of anticoagulants (e.g., warfarin, heparin, DOACs) due to potential anticoagulant effects of quercetin/curcumin.
- Acute illness at the time of screening.
- Pregnancy or breastfeeding.
- Use of immunosuppressive medications or corticosteroids within the past month.
- Significant psychiatric disorder that may interfere with study compliance.
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Liaquat University of Medical & Health Sciences (LUMHS)
Jamshoro, Sindh, 76090
About this study
Official title: Evaluation of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms: A Pragmatic, Interventional Clinical Study.
This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. The primary outcome is the improvement in overall symptom burden, while secondary outcomes include changes in quality of life, the need for NSAIDs, and inflammatory markers. The study seeks to provide real-world evidence of the potential benefits of this combined supplement in managing Long COVID-19 symptoms.
Read the detailed description
Long COVID-19, characterized by persistent symptoms lasting weeks or months after the acute phase of SARS-CoV-2 infection, presents a significant challenge for healthcare systems and affected individuals. Common symptoms include fatigue, brain fog, muscle pain, joint pain, sleep disturbances, and generalized weakness. Despite extensive research, there are limited effective therapeutic options for managing Long COVID-19 symptoms.
Quercetin and curcumin, two natural compounds with well-documented anti-inflammatory, antioxidant, and immunomodulatory properties, have gained attention for their potential benefits in various inflammatory and infectious conditions. Quercetin, a flavonoid found in various fruits and vegetables, has been shown to inhibit pro-inflammatory cytokines, reduce oxidative stress, and modulate immune responses. Curcumin, a polyphenol derived from turmeric (Curcuma longa), is known for its strong anti-inflammatory and antioxidant properties and has demonstrated immune-modulating effects in clinical studies.
Nasafytol® is a standardized combination supplement containing bioactive quercetin (65 mg) and curcumin (42 mg) from Curcuma longa, specifically formulated to enhance bioavailability and provide synergistic benefits. Both quercetin and curcumin in Nasafytol® are optimized for absorption and efficacy, making it a promising intervention for managing inflammatory and immune-related conditions.
The combination of quercetin and curcumin in Nasafytol® is hypothesized to provide synergistic benefits in managing Long COVID-19 symptoms. This pragmatic clinical study aims to evaluate the efficacy of Nasafytol® in reducing symptom burden and improving quality of life in adults experiencing mild to moderate Long COVID-19 symptoms. Participants will receive the combined supplement for two months, with primary outcomes focused on symptom improvement and secondary outcomes assessing changes in quality of life, the need for NSAIDs, and inflammatory markers.
The study is designed as a real-world pragmatic trial to provide evidence of the potential health benefits of Nasafytol® for Long COVID-19, addressing a critical gap in current management strategies.
- Conditions
- Long COVID
- Being tested
- Nasafytol® (Quercetin/Curcumin Supplement)
- Medical subject headings
- Post-Acute COVID-19 Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nasafytol® (Quercetin/Curcumin Supplement)Dietary supplement
Participants in this group will receive Nasafytol®, a combined dietary supplement containing quercetin (65 mg) and curcumin (42 mg). Participants will take two capsules (single administration) twice a day for a duration of 8 weeks. The supplement is intended to alleviate mild to moderate symptoms of Long COVID-19, including but not limited to fatigue, cognitive function, generalized body pain, low mood, sleep disturbance, and overall quality of life.
| Study group | Role | What they receive |
|---|---|---|
| Nasafytol® Group (Quercetin/Curcumin Supplement Group) | Experimental | Participants in this group will receive a combined supplement of Nasafytol®, containing quercetin (65 mg) and curcumin (42 mg). Participants will be instructed to take two capsules (single administration) twice a day for 8 weeks. Receives: Dietary Supplement: Nasafytol® (Quercetin/Curcumin Supplement) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Overall Symptom Burden
Assessment of overall symptom burden using the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS). Improvement will be defined as either a ≥2-point reduction in any single symptom domain or a ≥10% reduction in the total C19-YRS symptom burden score from baseline.
Measured: 8 weeks
Secondary outcomes (7)
Change in Functional Status and Quality of Life (SF-36 Scores)
Assessment of quality of life using the SF-36 Health Survey, which evaluates eight domains, including physical functioning, bodily pain, general health, vitality, social functioning, and emotional well-being. It provides two summary scores: physical and mental health components.
Measured: 8 weeks
Change in the Need for Prescribed Medications or NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
Monitoring the frequency and dosage of prescribed medications or NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) used for symptom relief. This will be recorded using a participant-maintained medication log.
Measured: 8 weeks
Change in Pain Severity and Pain Interference (Brief Pain Inventory - Short Form)
The Brief Pain Inventory - Short Form (BPI-SF) is a validated, self-reported questionnaire that assesses the severity of pain and the impact of pain on daily functioning. The instrument includes items measuring pain intensity (worst, least, average, and current pain) and pain interference with general activity, mood, walking ability, normal work, relations with others, sleep, and enjoyment of life. Scores range from 0 to 10, with higher scores indicating greater pain severity or interference.
Measured: 8 weeks
Change in Fatigue Severity (Fatigue Severity Scale)
The Fatigue Severity Scale (FSS) is a 9-item, self-administered questionnaire designed to assess the severity of fatigue and its impact on daily activities and functioning. Each item is rated on a 7-point Likert scale, with higher scores indicating greater fatigue severity.
Measured: 8 weeks
Change in Anxiety and Depression Symptoms (Hospital Anxiety and Depression Scale)
The Hospital Anxiety and Depression Scale (HADS) is a validated, 14-item self-report instrument used to assess symptoms of anxiety and depression. It consists of two subscales (anxiety and depression), each with 7 items. Subscale scores range from 0 to 21, with higher scores indicating greater symptom severity.
Measured: 8 weeks
Change in Sleep Quality (Pittsburgh Sleep Quality Index)
The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported questionnaire that assesses sleep quality and sleep disturbances over a 1-month interval. It consists of 19 items generating seven component scores and a global score ranging from 0 to 21, with higher scores indicating poorer sleep quality.
Measured: 8 weeks
Change in Cognitive Function (PROMIS Cognitive Function - Short Form 8a)
The PROMIS® Cognitive Function - Short Form 8a is a validated, patient-reported outcome measure assessing perceived cognitive abilities, including memory, attention, and mental clarity. The instrument consists of 8 items and is scored using standardized T-scores, with higher scores indicating better cognitive function.
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2025
- Study start22 Jul 2025
- Primary completion18 Nov 2025
- Study completion14 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a pragmatic, open-label clinical study evaluating the benefits of a combined quercetin/curcumin supplement (Nasafytol®) in adults experiencing mild to moderate Long COVID-19 symptoms.
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Liaquat University of Medical & Health Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Amjad Khan, Liaquat University of Medical & Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06974058
- Sponsor's protocol ID
- LUMHS/REC/-735/13.05.2025
- Status last verified
- Dec 2025
- First submitted
- 12 May 2025
- Last updated
- 19 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Vollbracht C, Kraft K. Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C. Front Pharmacol. 2022 Apr 29;13:899198. doi: 10.3389/fphar.2022.899198. eCollection 2022.
PubMed 35571085Vlaming-van Eijk LE, Bulthuis MLC, van der Gun BTF, Wold KI, Veloo ACM, Vincenti Gonzalez MF, de Borst MH, den Dunnen WFA, Hillebrands JL, van Goor H, Tami A, Bourgonje AR. Systemic oxidative stress associates with the development of post-COVID-19 syndrome in non-hospitalized individuals. Redox Biol. 2024 Oct;76:103310. doi: 10.1016/j.redox.2024.103310. Epub 2024 Aug 19.
PubMed 39163767Al-Hakeim HK, Al-Rubaye HT, Al-Hadrawi DS, Almulla AF, Maes M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol Psychiatry. 2023 Feb;28(2):564-578. doi: 10.1038/s41380-022-01836-9. Epub 2022 Oct 24.
PubMed 36280755Gerain J, Uebelhoer M, Costes B, Herman J, Pietri S, Donneau AF, Monseur J, Henrotin Y. NASAFYTOL(R) supplementation in adults hospitalized with COVID-19 infection: results from an exploratory open-label randomized controlled trial. Front Nutr. 2023 Jun 22;10:1137407. doi: 10.3389/fnut.2023.1137407. eCollection 2023.
PubMed 37426178Khan A, Iqtadar S, Mumtaz SU, Heinrich M, Pascual-Figal DA, Livingstone S, Abaidullah S. Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19-Results From a Pilot Open-Label, Randomized Controlled Trial. Front Pharmacol. 2022 Jun 7;13:898062. doi: 10.3389/fphar.2022.898062. eCollection 2022.
PubMed 35747751Ujjan ID, Khan S, Nigar R, Ahmed H, Ahmad S, Khan A. The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19-Results from a pragmatic randomized clinical trial. Front Nutr. 2023 Jan 18;9:1023997. doi: 10.3389/fnut.2022.1023997. eCollection 2022.
PubMed 36742008Khan A, Rabbani F, Mumtaz SU, Javed R, Ujjan I, Kanwal A, Conti G. Potential Adjunctive Effects of Quercetin-Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study. Pharmaceuticals (Basel). 2026 Jul 31;19(8):1202. doi: 10.3390/ph19081202.
PubMed 42653699
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms: A Pragmatic, Interventional Clinical Study.
- ClinicalTrials.gov ID
- NCT06974058
- Acronym / sponsor ID
- LUMHS/REC/-735/13.05.2025
- Conditions
- Long COVID
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Liaquat University of Medical & Health SciencesUniversity, hospital or other
- Study start
- 22 Jul 2025 (actual)
- Primary completion
- 18 Nov 2025 (actual)
- Study completion
- 14 Dec 2025 (actual)
- First posted
- 15 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. The primary outcome is the improvement in overall symptom burden, while secondary outcomes include changes in quality of life, the need for NSAIDs, and inflammatory markers. The study seeks to provide real-world evidence of the potential benefits of this combined supplement in managing Long COVID-19 symptoms.
Detailed description
Long COVID-19, characterized by persistent symptoms lasting weeks or months after the acute phase of SARS-CoV-2 infection, presents a significant challenge for healthcare systems and affected individuals. Common symptoms include fatigue, brain fog, muscle pain, joint pain, sleep disturbances, and generalized weakness. Despite extensive research, there are limited effective therapeutic options for managing Long COVID-19 symptoms.
Quercetin and curcumin, two natural compounds with well-documented anti-inflammatory, antioxidant, and immunomodulatory properties, have gained attention for their potential benefits in various inflammatory and infectious conditions. Quercetin, a flavonoid found in various fruits and vegetables, has been shown to inhibit pro-inflammatory cytokines, reduce oxidative stress, and modulate immune responses. Curcumin, a polyphenol derived from turmeric (Curcuma longa), is known for its strong anti-inflammatory and antioxidant properties and has demonstrated immune-modulating effects in clinical studies.
Nasafytol® is a standardized combination supplement containing bioactive quercetin (65 mg) and curcumin (42 mg) from Curcuma longa, specifically formulated to enhance bioavailability and provide synergistic benefits. Both quercetin and curcumin in Nasafytol® are optimized for absorption and efficacy, making it a promising intervention for managing inflammatory and immune-related conditions.
The combination of quercetin and curcumin in Nasafytol® is hypothesized to provide synergistic benefits in managing Long COVID-19 symptoms. This pragmatic clinical study aims to evaluate the efficacy of Nasafytol® in reducing symptom burden and improving quality of life in adults experiencing mild to moderate Long COVID-19 symptoms. Participants will receive the combined supplement for two months, with primary outcomes focused on symptom improvement and secondary outcomes assessing changes in quality of life, the need for NSAIDs, and inflammatory markers.
The study is designed as a real-world pragmatic trial to provide evidence of the potential health benefits of Nasafytol® for Long COVID-19, addressing a critical gap in current management strategies.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a pragmatic, open-label clinical study evaluating the benefits of a combined quercetin/curcumin supplement (Nasafytol®) in adults experiencing mild to moderate Long COVID-19 symptoms.
| Arm | Type | Receives |
|---|---|---|
| Nasafytol® Group (Quercetin/Curcumin Supplement Group) | Experimental | Dietary Supplement: Nasafytol® (Quercetin/Curcumin Supplement)Participants in this group will receive a combined supplement of Nasafytol®, containing quercetin (65 mg) and curcumin (42 mg). Participants will be instructed to take two capsules (single administration) twice a day for 8 weeks. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age: 18 to 75 years.
- History of confirmed COVID-19 infection at least 6 months prior to the enrollment.
- Persistent mild to moderate COVID-19 symptoms for at least 3 months post-acute infection.
- Diagnosis of Long COVID-19 based on WHO criteria.
- Symptom burden score of ≥25 at baseline (V0) on the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS).
Key exclusion criteria (8 listed)
- Hypersensitivity or allergy to quercetin, curcumin, or any component of the supplement (Nasafytol®).
- Severe, uncontrolled chronic illness (e.g., severe heart failure, chronic kidney disease requiring dialysis, severe liver disease).
- Regular use of quercetin or curcumin supplements within the last 3 months.
- Use of anticoagulants (e.g., warfarin, heparin, DOACs) due to potential anticoagulant effects of quercetin/curcumin.
- Acute illness at the time of screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nasafytol® (Quercetin/Curcumin Supplement)Participants in this group will receive Nasafytol®, a combined dietary supplement containing quercetin (65 mg) and curcumin (42 mg). Participants will take two capsules (single administration) twice a day for a duration of 8 weeks. The supplement is intended to alleviate mild to moderate symptoms of Long COVID-19, including but not limited to fatigue, cognitive function, generalized body pain, low mood, sleep disturbance, and overall quality of life. | Dietary supplement | Nasafytol® Group (Quercetin/Curcumin Supplement Group) |
Primary outcome
Change in Overall Symptom Burden
Time frame: 8 weeks
Assessment of overall symptom burden using the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS). Improvement will be defined as either a ≥2-point reduction in any single symptom domain or a ≥10% reduction in the total C19-YRS symptom burden score from baseline.
7 secondary outcomes
Change in Functional Status and Quality of Life (SF-36 Scores)
Time frame: 8 weeks
Change in the Need for Prescribed Medications or NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
Time frame: 8 weeks
Change in Pain Severity and Pain Interference (Brief Pain Inventory - Short Form)
Time frame: 8 weeks
Change in Fatigue Severity (Fatigue Severity Scale)
Time frame: 8 weeks
Change in Anxiety and Depression Symptoms (Hospital Anxiety and Depression Scale)
Time frame: 8 weeks
Change in Sleep Quality (Pittsburgh Sleep Quality Index)
Time frame: 8 weeks
Change in Cognitive Function (PROMIS Cognitive Function - Short Form 8a)
Time frame: 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2025.
- Background: PubMed 35571085Vollbracht C, Kraft K. Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C. Front Pharmacol. 2022 Apr 29;13:899198. doi: 10.3389/fphar.2022.899198. eCollection 2022.
- Background: PubMed 39163767Vlaming-van Eijk LE, Bulthuis MLC, van der Gun BTF, Wold KI, Veloo ACM, Vincenti Gonzalez MF, de Borst MH, den Dunnen WFA, Hillebrands JL, van Goor H, Tami A, Bourgonje AR. Systemic oxidative stress associates with the development of post-COVID-19 syndrome in non-hospitalized individuals. Redox Biol. 2024 Oct;76:103310. doi: 10.1016/j.redox.2024.103310. Epub 2024 Aug 19.
- Background: PubMed 36280755Al-Hakeim HK, Al-Rubaye HT, Al-Hadrawi DS, Almulla AF, Maes M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol Psychiatry. 2023 Feb;28(2):564-578. doi: 10.1038/s41380-022-01836-9. Epub 2022 Oct 24.
- Background: PubMed 37426178Gerain J, Uebelhoer M, Costes B, Herman J, Pietri S, Donneau AF, Monseur J, Henrotin Y. NASAFYTOL(R) supplementation in adults hospitalized with COVID-19 infection: results from an exploratory open-label randomized controlled trial. Front Nutr. 2023 Jun 22;10:1137407. doi: 10.3389/fnut.2023.1137407. eCollection 2023.
- Background: PubMed 35747751Khan A, Iqtadar S, Mumtaz SU, Heinrich M, Pascual-Figal DA, Livingstone S, Abaidullah S. Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19-Results From a Pilot Open-Label, Randomized Controlled Trial. Front Pharmacol. 2022 Jun 7;13:898062. doi: 10.3389/fphar.2022.898062. eCollection 2022.
- Background: PubMed 36742008Ujjan ID, Khan S, Nigar R, Ahmed H, Ahmad S, Khan A. The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19-Results from a pragmatic randomized clinical trial. Front Nutr. 2023 Jan 18;9:1023997. doi: 10.3389/fnut.2022.1023997. eCollection 2022.
- Derived from this study: PubMed 42653699Khan A, Rabbani F, Mumtaz SU, Javed R, Ujjan I, Kanwal A, Conti G. Potential Adjunctive Effects of Quercetin-Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study. Pharmaceuticals (Basel). 2026 Jul 31;19(8):1202. doi: 10.3390/ph19081202.
- Individual participant dataSharing planned: No
Related trials for Long COVID
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nasafytol® (Quercetin/Curcumin Supplement) in people with Long COVID, run by Liaquat University of Medical & Health Sciences at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Overall Symptom Burden (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06974058, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2025.